Thursday, April 21, 2016 1:05:12 PM
Licensing is still the strategy. No way they intend to build any type of manufacturing facility to go it alone there. Can you imagine Dahl seeking funding for manufacturing after potentially finishing a feed/food ingredient ?? ROFLMAO .... would take decades.
And yes you generally need something tangible to show a potential licensee why they need your product. But other qualified companies need to get paid to do the development work needed (see the update). Which takes ZIVO raising money. It is obvious Dahl cannot sell the idea. So it drags on and on forever.
At this juncture I believe that ZIVO does have plenty of tangible lab and now field tested proof. The safety studies IMO are formality. I doubt there is any toxicity. IMO it is whether or not there is evidence the ingredient does something of value (which the research says it does) for the end consumer and can it be produced and sold profitably.
I still advocate a JV with a company that has the expertise and can do the work from beginning to end ..... it is a no brainer for a company like ZIVO for one vertical to gain some traction in the market and a name for itself. ZIVO contributes the IP and a % of the JV in exchange for the expertise (i.e. sweat equity so to speak) to drive the vertical to completion. The partner has a vested interest in seeing their contribution pay off by generating revenues and profits. A fractional % of a JV producing revenue is more than ALL of NOTHING. Which is what we have now. By the time the first candidate gets to commercial stage ... if ever ... the stock likely will be diluted to death. It is presently at a stage where it would take significant profits to dent the per share number with any significance which limits upside potential .... which of course makes it far less attractive to me. And since per share price is near all time lows, any dilution is significant which further weighs on stock price.
Only thing interesting in the update to me was the mention of a feed pellet ...... but didn't mention who is doing that.
So we shall see but most of my time and money is working on other companies presently. Many fertile playgrounds elsewhere.
Amigo Mike
Recent ZIVO News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/26/2024 05:36:56 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/26/2024 12:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 04/09/2024 03:49:14 PM
- Form SCHEDULE 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/14/2024 01:16:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:45:37 PM
- Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 02/15/2024 01:54:37 PM
- ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study • Business Wire • 02/07/2024 09:54:00 PM
- ZIVO Bioscience Announces Uplisting to OTCQB Market • Business Wire • 01/29/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:11:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2024 10:17:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:05:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:23:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 09:12:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 02:29:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2023 09:21:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 09:18:41 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 10/30/2023 05:20:31 PM
- ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens • Business Wire • 10/30/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/26/2023 12:56:59 PM
- ZIVO Bioscience Announces Reverse Stock Split • Business Wire • 10/26/2023 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 10/04/2023 09:08:51 PM
- ZIVO Bioscience to Present at the Dawson James Small Cap Growth Conference • GlobeNewswire Inc. • 10/03/2023 12:30:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM